Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

被引：0
|
作者：
U Platzbecker
F Braulke
A Kündgen
K Götze
G Bug
C Schönefeldt
K Shirneshan
C Röllig
M Bornhäuser
R Naumann
J Neesen
A Giagounidis
W-K Hofmann
G Ehninger
U Germing
D Haase
M Wermke
机构：
[1] Medical Clinic and Polyclinic I,Department of Hematology and Oncology
[2] University Hospital,Department of Hematology and Oncology
[3] Technical University Dresden,undefined
[4] University Hospital,undefined
[5] University Göttingen,undefined
[6] University Hospital,undefined
[7] Heinrich Heine University Düsseldorf,undefined
[8] Medical Clinic,undefined
[9] University Hospital,undefined
[10] Technical University Munich,undefined
[11] Clinic of Hematology and Oncology,undefined
[12] J.W. Goethe University Hospital,undefined
[13] Stiftungsklinikum Mittelrhein,undefined
[14] Institute of Medical Genetics,undefined
[15] Medical University Vienna,undefined
[16] St Johannes Hospital,undefined
[17] Clinic of Hematology and Oncology,undefined
[18] Hospital of the Ruprecht Karls University,undefined
来源：
Leukemia | 2013年 / 27卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1403 / 1407
页数：4
相关论文
共 50 条
  • [41] Azacitidine and Lenalidomide Combination In Higher-Risk Myelodysplastic Syndromes-Preliminary Results Of The Vilen-01 Protocol
    Mittelman, Moshe
    Filanovsky, Kalman
    Rosenbaum, Hanna
    Raanani, Pia
    Braester, Andrei
    Goldschmidt, Neta
    Hellman, Ilana
    Kirgner, Ilya
    Perrii, Chava
    Oster, Howard S.
    BLOOD, 2013, 122 (21)
  • [42] Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome
    Narayan, Rupa
    Garcia, Jacqueline S.
    Percival, Mary-Elizabeth M.
    Berube, Caroline
    Coutre, Steve
    Gotlib, Jason
    Greenberg, Peter
    Liedtke, Michaela
    Hewitt, Rhonda
    Regan, Kathleen
    Williamson, Charles
    Doykan, Camille
    Cardone, Michael H.
    McMillan, Alex
    Medeiros, Bruno C.
    LEUKEMIA & LYMPHOMA, 2016, 57 (03) : 609 - 615
  • [43] Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia: Effects on Marrow Recovery and Transfusion Independence
    Zeidan, Amer
    Schuster, Michael
    Joris, Magalie
    Krauter, Juergen
    Maertens, Johan
    Gyan, Emmanuel
    Kovacsovics, Tibor
    Verma, Amit
    Vyas, Paresh
    Wang, Eunice
    Ma, Weidong
    Zeremski, Mirjana
    Kudla, Arthur
    Chan, Geoffrey
    Sekeres, Mikkael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S191 - S192
  • [44] A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML)
    Navada, S. C.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Alvarado, Y.
    Daver, N.
    DiNardo, C.
    Konopleva, M.
    Borthakur, G.
    Azarnia, N.
    Silverman, L. R.
    LEUKEMIA RESEARCH, 2015, 39 : S45 - S45
  • [45] Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes
    Heise, Carla
    Carter, Troy
    Schafer, Peter
    Chopra, Rajesh
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (10) : 1663 - 1672
  • [46] Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide
    Gerds, Aaron T.
    List, Alan F.
    Giagounidis, Aristoteles
    Hellstrom-Lindberg, Eva
    Li, Jack Shiansong
    Swern, Arlene S.
    Sugrue, Mary M.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)
  • [47] Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations
    Mallo, Mar
    del Rey, Monica
    Ibanez, Mariam
    Jose Calasanz, Ma
    Arenillas, Leonor
    Jose Larrayoz, Ma
    Pedro, Carmen
    Jerez, Andres
    Maciejewski, Jaroslaw
    Costa, Dolors
    Nomdedeu, Meritxell
    Diez-Campelo, Maria
    Lumbreras, Eva
    Gonzalez-Martinez, Teresa
    Marugan, Isabel
    Such, Esperanza
    Cervera, Jose
    Cigudosa, Juan C.
    Alvarez, Sara
    Florensa, Lourdes
    Hernandez, Jesus Ma
    Sole, Francesc
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (01) : 74 - 86
  • [48] Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
    Vozella, Federico
    Latagliata, Roberto
    Carmosino, Ida
    Volpicelli, Paola
    Montagna, Chiara
    Romano, Angela
    Roberto, Amanda
    Finsinger, Paola
    Mancini, Marco
    Breccia, Massimo
    Oliva, Esther
    Alimena, Giuliana
    HEMATOLOGICAL ONCOLOGY, 2015, 33 (01) : 48 - 51
  • [49] Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia
    Kenealy, Melita
    Hertzberg, Mark
    Benson, Warwick
    Taylor, Kerry
    Cunningham, Ilona
    Stevenson, Will
    Hiwase, Devendra
    Eek, Richard
    Zantomio, Daniela
    Jong, Steve
    Wall, Meaghan
    Blombery, Piers
    Gerber, Tracey
    Debrincat, Marlyse
    Zannino, Diana
    Seymour, John F.
    HAEMATOLOGICA, 2019, 104 (04) : 700 - 709
  • [50] Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes
    Kota, Vamsi
    Ogbonnaya, Augustina
    Farrelly, Eileen
    Schroader, Bridgette Kanz
    Raju, Aditya
    Kristo, Fjoralba
    Dalal, Mehul
    FUTURE ONCOLOGY, 2022, 18 (36) : 4017 - 4029
12345